Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease ConferenceGlobeNewsWire • 11/20/25
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral ImpairmentsGlobeNewsWire • 11/17/25
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral ImpairmentsBusiness Wire • 11/17/25
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular AtrophyGlobeNewsWire • 11/17/25
Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit TranscriptSeeking Alpha • 11/13/25
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United KingdomGlobeNewsWire • 11/13/25
Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks TranscriptSeeking Alpha • 11/10/25
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025GlobeNewsWire • 11/03/25
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS ViewZacks Investment Research • 10/30/25
Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/30/25
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's DiseaseGlobeNewsWire • 10/26/25
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the KeyZacks Investment Research • 10/24/25
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology PortfolioGlobeNewsWire • 10/24/25
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/23/25
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025GlobeNewsWire • 10/22/25
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes TurnaroundThe Motley Fool • 10/20/25
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”GlobeNewsWire • 10/13/25